Pre-clinical and clinical applications of small interfering rnas (Sirna) and co-delivery systems for pancreatic cancer therapy

Basit Öğe Kaydı
dc.authoridAli Zarrabi / 0000-0003-0391-1769en_US
dc.authorscopusidAli Zarrabi / 23483174100en_US
dc.authorwosidAli Zarrabi / U-2602-2019
dc.contributor.authorMirzaei S.
dc.contributor.authorGholami M.H.
dc.contributor.authorAng H.L.
dc.contributor.authorHashemi F.
dc.contributor.authorZarrabi A.
dc.contributor.authorZabolian A.
dc.contributor.authorHushmandi K.
dc.contributor.authorDelfi M.
dc.date.accessioned2021-12-07T05:28:08Z
dc.date.available2021-12-07T05:28:08Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümüen_US
dc.description.abstractPancreatic cancer (PC) is one of the leading causes of death and is the fourth most malignant tumor in men. The epigenetic and genetic alterations appear to be responsible for development of PC. Small interfering RNA (siRNA) is a powerful genetic tool that can bind to its target and reduces expression level of a specific gene. The various critical genes involved in PC progression can be effectively targeted using diverse siRNAs. Moreover, siRNAs can enhance efficacy of chemotherapy and radiotherapy in inhibiting PC progression. However, siRNAs suffer from different off target effects and their degradation by enzymes in serum can diminish their potential in gene silencing. Loading siRNAs on nanoparticles can effectively protect them against degradation and can inhibit off target actions by facilitating targeted delivery. This leads to enhanced efficacy of siRNAs in PC therapy. Moreover, different kinds of nanoparticles such as polymeric nanoparticles, lipid nanoparticles and metal nanostructures have been applied for optimal delivery of siRNAs that are discussed in this article. This review also reveals that how naked siRNAs and their delivery systems can be exploited in treatment of PC and as siRNAs are currently being applied in clinical trials, significant progress can be made by translating the current findings into the clinical settings.en_US
dc.identifier.citationMirzaei, S., Gholami, M. H., Ang, H. L., Hashemi, F., Zarrabi, A., Zabolian, A., ... & Kumar, A. P. (2021). Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Cells, 10(12), 3348.en_US
dc.identifier.doi10.3390/cells10123348en_US
dc.identifier.issn2073-4409en_US
dc.identifier.pmid34943856en_US
dc.identifier.scopus2-s2.0-85120054055en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3390/cells10123348
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2308
dc.identifier.wosWOS:000736247400001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorZarrabi, Ali
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofCellsen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCo-Deliveryen_US
dc.subjectDrug Resistanceen_US
dc.subjectNanoparticlesen_US
dc.subjectPancreatic Canceren_US
dc.subjectSmall Interfering RNA (siRNA)en_US
dc.titlePre-clinical and clinical applications of small interfering rnas (Sirna) and co-delivery systems for pancreatic cancer therapyen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
237.pdf
Boyut:
3.07 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Biyomedikal Mühendisliği Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu